PURE News and Press, Pure Bioscience Inc

2025-12-15 16:23:31 ET More on PURE Bioscience Seeking Alpha’s Quant Rating on PURE Bioscience Financial information for PURE Bioscience Read the full article on Seeking Alpha For further details see: PURE Bioscience GAAP EPS of $0.00, revenue of $...

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2025. S...

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE” or the “Company”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today announced that the Company has appointed Jeff Kitchell as President, in addition to his ongoing responsibil...

2025-10-29 17:07:05 ET More on PURE Bioscience Seeking Alpha’s Quant Rating on PURE Bioscience Financial information for PURE Bioscience Read the full article on Seeking Alpha For further details see: PURE Bioscience GAAP EPS of -$0.02, revenue of ...

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal year ended July 31, 2025. Summary of Re...

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial and Bonsai (“Bonsai”), has entered into a multi-year distribution agreement ...

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2025. Sum...

BriaCell Therapeutics Corp. (BCTX) is expected to report $-1.76 for Q3 2025 KT Corporation (KT) is expected to report for Q1 2025 OpenLocker Holdings Inc (OLKR) is expected to report for Q3 2025 180 Degree Capital Corp. (TURN) is expected to report for Q1 2025 Finch Therapeutics G...

Pure Bioscience Inc (PURE) is expected to report for Q3 2025

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, is proud to announce an innovative application method for membrane treatment in the dairy and...